$1.01 Billion is the total value of GREAT POINT PARTNERS LLC's 41 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -317,962 | -100.0% | -0.02% | – |
| ARGX | Exit | ARGENX SEsponsored adr | $0 | – | -18,500 | -100.0% | -0.22% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCcall | $0 | – | -26,000 | -100.0% | -0.32% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCput | $0 | – | -26,000 | -100.0% | -0.32% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -40,197 | -100.0% | -0.37% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -27,500 | -100.0% | -0.39% | – |
| VYGR | Exit | VOYAGER THERAPEUTICS INC | $0 | – | -365,132 | -100.0% | -0.43% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INCput | $0 | – | -400,000 | -100.0% | -0.58% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -955,618 | -100.0% | -0.81% | – |
| AMAG | Exit | AMAG PHARMACEUTICALS INC | $0 | – | -664,681 | -100.0% | -1.28% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -143,481 | -100.0% | -1.28% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -3,000,000 | -100.0% | -1.56% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -3,173,288 | -100.0% | -2.54% | – |
| ONCE | Exit | SPARK THERAPEUTICS INC | $0 | – | -630,600 | -100.0% | -3.12% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INCput | $0 | – | -200,000 | -100.0% | -4.19% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.